Skip to main content
SpringerLink
Log in
Book cover

Stereotactic Radiosurgery for Prostate Cancer pp 93–110Cite as

Overview of Tumor Control Outcomes with Prostate SBRT for Low and Intermediate Risk Prostate Cancer and Comparison to Other Treatment Interventions

  • Chapter
  • First Online:

  • 601 Accesses

Abstract

Treatment of prostate cancer has evolved significantly over the last decade. Active surveillance has been established as the primary treatment for low risk disease. National and international guidelines state that for a patient with low risk localized prostate cancer, brachytherapy (BT), external beam radiotherapy (EBRT) and radical prostatectomy (RP) are appropriate monotherapy options and the outcomes data do not provide a clear-cut evidence for the superiority of any one treatment. Available evidence suggests that there is no difference in clinical progression, incidence of metastases or overall survival between RP or EBRT for low risk patients. Similarly, the paradigm for intermediate risk prostate cancer has shifted with introduction of low-tier and high tier intermediate risk categories. While the low-tier intermediate risk patients are treated with one of many available treatment modalities and difference in clinical outcomes has been shown for those receiving prostatectomy or radiotherapy; high-tier intermediate risk patients, on the other hand have better outcome with combination of EBRT and BT. There is emerging, albeit early evidence that hypofractionated radiotherapy regimens may be appropriate choice in select low-risk and low-tier intermediate risk patients as monotherapy, as well as for select high-tier intermediate risk patients in combination with brachytherapy. In this chapter, we summarize key clinical series and trials to highlight differences in the outcomes among various treatment modalities utilized for treatment of localized prostate cancer and compare those to extreme hypofractionated regimens also known as stereotactic body radiotherapy (SBRT).

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999;43(5):1095–101.

    Article  CAS  PubMed  Google Scholar 

  2. Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD, Armour EP. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys. 2002;52(1):6–13.

    Article  PubMed  Google Scholar 

  3. Dasu A. Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials? Clin Oncol (R Coll Radiol). 2007;19(5):289–301.

    Article  CAS  Google Scholar 

  4. Schuessler WW, Schulam PG, Clayman RV, Kavoussi LR. Laparoscopic radical prostatectomy: initial short-term experience. Urology. 1997;50(6):854–7.

    Article  CAS  PubMed  Google Scholar 

  5. Binder J, Kramer W. Robotically-assisted laparoscopic radical prostatectomy. BJU Int. 2001;87(4):408–10.

    Article  CAS  PubMed  Google Scholar 

  6. Louis AS, Kalnin R, Maganti M, Pintilie M, Matthew AG, Finelli A, et al. Oncologic outcomes following radical prostatectomy in the active surveillance era. Can Urol Assoc J. 2013;7(7–8):e475–80.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Mullins JK, Feng Z, Trock BJ, Epstein JI, Walsh PC, Loeb S. The impact of anatomical radical retropubic prostatectomy on cancer control: the 30-year anniversary. J Urol. 2012;188(6):2219–24.

    Article  PubMed  Google Scholar 

  8. Røder MA, Berg KD, Gruschy L, Brasso K, Cancer IP. First Danish single-institution experience with radical prostatectomy: biochemical outcome in 1200 consecutive patients. Prostate Cancer. 2011;2011:5.

    Article  Google Scholar 

  9. Diaz M, Peabody JO, Kapoor V, Sammon J, Urology RCG. Oncologic outcomes at 10 years following robotic radical prostatectomy. Eur Urol. 2015;67(6):1168–76.

    Article  PubMed  Google Scholar 

  10. Kane CJ, Im R, Amling CL, Presti JC, Aronson WJ, Terris MK, et al. Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database. Urology. 2010;76(3):695–700.

    Article  PubMed  Google Scholar 

  11. Menon M, Bhandari M, Gupta N, Lane Z, Peabody JO, Rogers CG, et al. Biochemical recurrence following robot-assisted radical prostatectomy: analysis of 1384 patients with a median 5-year follow-up. Eur Urol. 2010;58(6):838–46.

    Article  PubMed  Google Scholar 

  12. Nivedita B-D, Reuther AM, Zippe C, Klein EA. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer. Urology. 2004;63(3):528–31.

    Article  Google Scholar 

  13. Zelefsky MJ, Fuks ZVI, Hunt M, Lee HJ, Lombardi D, Ling C, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol. 2001;166(3):876–81.

    Article  CAS  PubMed  Google Scholar 

  14. Pollack A, Zagars GK, Starkschall G, Antolak JA. Prostate cancer radiation dose response: results of the MD Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53(5):1097–105.

    Article  PubMed  Google Scholar 

  15. Peeters S, Heemsbergen WD, Koper P, van Putten W, Slot A, Dielwart M, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006;24(13):1990–6.

    Article  PubMed  Google Scholar 

  16. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(1):67–74.

    Article  PubMed  Google Scholar 

  17. Heemsbergen WD, Abrahim A-M, Slot A, Dielwart MF, Lebesque JV. Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiother Oncol. 2014;110(1):104–9.

    Article  PubMed  Google Scholar 

  18. Zelefsky MJ, Yamada Y, Fuks Z, Zhang Z, Hunt M, Cahlon O, et al. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys. 2008;71(4):1028–33.

    Article  PubMed  Google Scholar 

  19. Eade TN, Hanlon AL, Horwitz EM, Buyyounouski MK, Hanks GE, Pollack A. What dose of external-beam radiation is high enough for prostate cancer? Int J Radiat Oncol Biol Phys. 2007;68(3):682–9.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan R, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007;8(6):475–87.

    Article  PubMed  Google Scholar 

  21. Kalbasi A, Li J, Berman A, Samuel S-M, Smaldone M, Uzzo RG, et al. Dose-escalated irradiation and overall survival in men with nonmetastatic prostate cancer. JAMA Oncol. 2015;1(7):897–906.

    Article  PubMed  Google Scholar 

  22. Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol. 2010;28(7):1106–11.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Lee RW, Dignam JJ, Amin MB, Bruner DW, Low D, Swanson GP, et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol. 2016;34(20):2325–32.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17(8):1047–60.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Pollack A, Walker G, Horwitz EM, Price R, Feigenberg S, Konski AA, et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol. 2013;31(31):3860–8.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Catton CN, Lukka H, Gu C-SS, Martin JM, Supiot S, Chung PWMWM, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol. 2017;35(17):1884–90.

    Article  PubMed  Google Scholar 

  27. Aluwini S, Pos F, Schimmel E, Krol S, van der Toorn PP, de Jager H, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. Lancet Oncol. 2016;17(4):464–74.

    Article  PubMed  Google Scholar 

  28. Royce T, Lee D, Keum N, Permpalung N, Chiew CJ, Epstein S, et al. Conventional versus hypofractionated radiation therapy for localized prostate cancer: a meta-analysis of randomized noninferiority trials. Eur Urol Focus. 2017; https://doi.org/10.1016/j.euf.2017.10.011.

  29. Zelefsky MJ, Deborah AK, Larry BL, Potters L, David CB, John CB, et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys. 2007;67(2):327–33.

    Article  PubMed  Google Scholar 

  30. Sylvester JE, Grimm PD, Wong J, Galbreath RW, Merrick G, Blasko JC. Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I(125) prostate brachytherapy in clinically localized prostate cancer: Seattle experience. Int J Radiat Oncol Biol Phys. 2011;81(2):376–81.

    Article  PubMed  Google Scholar 

  31. Morris WJ, Keyes M, Spadinger I, Kwan W, Liu M, McKenzie M, et al. Population-based 10-year oncologic outcomes after low-dose-rate brachytherapy for low-risk and intermediate-risk prostate cancer. Cancer. 2013;119(8):1537–46.

    Article  PubMed  Google Scholar 

  32. Herbert C, James WM, Keyes M, Hamm J, Lapointe V, McKenzie M, et al. Outcomes following iodine-125 brachytherapy in patients with Gleason 7, intermediate risk prostate cancer: a population-based cohort study. Radiother Oncol [Internet]. 2012;103(2):228–32.

    Article  Google Scholar 

  33. Sekiguchi A, Ishiyama H, Satoh T, Tabata K, Komori S, Tsumura H, et al. 125Iodine monotherapy for Japanese men with low- and intermediate-risk prostate cancer: outcomes after 5 years of follow-up. J Radiat Res. 2014;55(2):328–33.

    Article  PubMed  Google Scholar 

  34. Kittel JA, Reddy CA, Smith KL, Stephans KL, Tendulkar RD, Ulchaker J, et al. Long-term efficacy and toxicity of low-dose-rate 125I prostate brachytherapy as monotherapy in low-, intermediate-, and high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2015;92(4):884–93.

    Article  PubMed  Google Scholar 

  35. Cosset J, Flam T, Belin L, Thiounn N, Pierrat N, Pontvert D, et al. Long-term results of permanent implant prostate cancer brachytherapy: a single-institution study of 675 patients treated between 1999 and 2003. Cancer Radiother. 2016;20(4):261–7.

    Article  PubMed  Google Scholar 

  36. Prestidge BR, Winter K, Sanda MG, Amin M, Bice WS, Michalski J, et al. Initial report of NRG oncology/RTOG 0232: a phase 3 study comparing combined external beam radiation and transperineal interstitial permanent brachytherapy with brachytherapy alone for selected patients with intermediate-risk prostatic carcinoma. Int J Radiat Oncol Biol Phys. 2016;96(2):S4.

    Article  Google Scholar 

  37. Frank SJ, Pugh TJ, Blanchard P, Mahmood U, Graber WJ, Kudchadker RJ, et al. Prospective phase 2 trial of permanent seed implantation prostate brachytherapy for intermediate-risk localized prostate cancer: efficacy, toxicity, and quality of life outcomes. Int J Radiat Oncol Biol Phys. 2018;100(2):374–82.

    Article  PubMed  Google Scholar 

  38. Kollmeier MA, Fidaleo A, Pei X, Cohen G, Zaider M, Mo Q, et al. Favourable long-term outcomes with brachytherapy-based regimens in men ≤60 years with clinically localized prostate cancer. BJU Int. 2013;111(8):1231–6.

    Article  PubMed  Google Scholar 

  39. Demanes DJ, Martinez AA, Ghilezan M, Hill DR, Schour L, Brandt D, et al. High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2011;81(5):1286–92.

    Article  PubMed  Google Scholar 

  40. Barkati M, Williams SG, Foroudi F, Tai KH, Chander S, van Dyk S, et al. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial. Int J Radiat Oncol Biol Phys. 2012;82(5):1889–96.

    Article  PubMed  Google Scholar 

  41. Hoskin P, Rojas A, Lowe G, Bryant L, Ostler P, Hughes R, et al. High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence. Int J Radiat Oncol Biol Phys. 2012;82(4):1376–84.

    Article  PubMed  Google Scholar 

  42. Zamboglou N, Tselis N, Baltas D, Buhleier T, Martin T, Milickovic N, et al. High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: treatment evolution and mature results. Int J Radiat Oncol Biol Phys. 2013;85(3):672–8.

    Article  PubMed  Google Scholar 

  43. Ghadjar P, Oesch SL, Rentsch CA, Isaak B, Cihoric N, Manser P, et al. Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer. Radiat Oncol. 2014;9:122.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Yoshioka Y, Suzuki O, Isohashi F, Seo Y. High-dose-rate brachytherapy as monotherapy for intermediate-and high-risk prostate cancer: clinical results for a median 8-year follow-up. Int J Radiat Oncol Biol Phys. 2016;94(4):675–82.

    Article  PubMed  Google Scholar 

  45. Jawad MS, Dilworth JT, Gustafson GS, Ye H, Wallace M, Martinez A, et al. Outcomes associated with 3 treatment schedules of high-dose-rate brachytherapy monotherapy for favorable-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2016;94(4):657–66.

    Article  PubMed  Google Scholar 

  46. Hauswald H, Kamrava MR, Fallon JM, Wang P-CC, Park S-JJ, Van T, et al. High-dose-rate monotherapy for localized prostate cancer: 10-year results. Int J Radiat Oncol Biol Phys. 2016;94(4):667–74.

    Article  PubMed  Google Scholar 

  47. Patel S, Demanes DJ, Ragab O, Zhang M, Veruttipong D, Nguyen K, et al. High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer. Brachytherapy. 2017;16(2):299–305.

    Article  PubMed  Google Scholar 

  48. Strouthos I, Tselis N, Chatzikonstantinou G, Butt S, Baltas D, Bon D, et al. High dose rate brachytherapy as monotherapy for localised prostate cancer. Radiother Oncol. 2018;126(2):270–7.

    Article  PubMed  Google Scholar 

  49. Prada PJ, Cardenal J, Blanco AG, Anchuelo J, Ferri M, Fernández G, et al. High-dose-rate interstitial brachytherapy as monotherapy in one fraction for the treatment of favorable stage prostate cancer: toxicity and long-term biochemical results. Radiother Oncol. 2016;119(3):411–6.

    Article  PubMed  Google Scholar 

  50. Mendenhall NP, Hoppe BS, Nichols RC, Mendenhall WM, Morris CG, Li Z, et al. Five-year outcomes from 3 prospective trials of image-guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2014;88(3):596–602.

    Article  PubMed  Google Scholar 

  51. Bryant C, Smith TL, Henderson RH, Hoppe BS, Mendenhall WM, Nichols RC, et al. Five-year biochemical results, toxicity, and patient-reported quality of life after delivery of dose-escalated image guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2016;95(1):422–34.

    Article  PubMed  Google Scholar 

  52. Henderson RH, Bryant C, Hoppe BS, Nichols CR, Mendenhall WM, Flampouri S, et al. Five-year outcomes from a prospective trial of image-guided accelerated hypofractionated proton therapy for prostate cancer. Acta Oncol (Madr). 2017;56(7):1–8.

    Article  Google Scholar 

  53. Takagi M, Demizu Y, Terashima K, Fujii O, Jin D, Niwa Y, et al. Long-term outcomes in patients treated with proton therapy for localized prostate cancer. Cancer Med. 2017;6(10):2234–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Collins CD, Lloyd-Davies RW, Swan AV. Radical external beam radiotherapy for localised carcinoma of the prostate using a hypofractionation technique. Clin Oncol (R Coll Radiol). 1991;3(3):127–32.

    Article  CAS  Google Scholar 

  55. Katz AJ, Santoro M, Diblasio F, Ashley R. Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. Radiat Oncol. 2013;8:118.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Tang CI, Loblaw DA, Cheung P, Holden L, Oncology MG. Phase I/II study of a five-fraction hypofractionated accelerated radiotherapy treatment for low-risk localised prostate cancer: early results of pHART3. Clin Oncol (R Coll Radiol). 2008;20(10):729–37.

    Article  CAS  Google Scholar 

  57. Martinez A, Gonzalez J, Spencer W, Gustafson G, Kestin L, Kearney D, et al. Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors. J Urol. 2003;169(3):974–80.

    Article  PubMed  Google Scholar 

  58. Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys. 2007;67(4):1099–105.

    Article  PubMed  Google Scholar 

  59. Bhattasali O, Chen LN, Woo J, Park J-WW, Kim JS, Moures R, et al. Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer. Radiat Oncol. 2014;9(1):52.

    Article  PubMed  PubMed Central  Google Scholar 

  60. King CR, Brooks JD, Gill H, Presti JC. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82(2):877–82.

    Article  PubMed  Google Scholar 

  61. McBride S, Wong D, Dombrowski JJ, Harkins B, Tepella P, Hanscom H, et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma. Cancer. 2012;118(15):3681–90.

    Article  PubMed  Google Scholar 

  62. Aluwini S, van Rooij P, Hoogeman M, Kirkels W, Kolkman-Deurloo I-K, Bangma C. Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results. Radiat Oncol. 2013;8:84.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Loblaw A, Cheung P, D'Alimonte L, Deabreu A, Mamedov A, Zhang L, et al. Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes. Radiother Oncol. 2013;107(2):153–8.

    Article  PubMed  Google Scholar 

  64. Katz AJ, Kang J. Stereotactic body radiotherapy as treatment for organ confined low- and intermediate-risk prostate carcinoma, a 7-year study. Front Oncol. 2014;4:240.

    PubMed  PubMed Central  Google Scholar 

  65. Katz A. Stereotactic body radiotherapy for low-risk prostate cancer: a ten-year analysis. Cureus. 2017;9(9):e1668.

    PubMed  PubMed Central  Google Scholar 

  66. Hannan R, Tumati V, Xie X-J, Cho LC, Kavanagh BD, Brindle J, et al. Stereotactic body radiation therapy for low and intermediate risk prostate cancer-Results from a multi-institutional clinical trial. Eur J Cancer. 2016;59:142–51.

    Article  PubMed  Google Scholar 

  67. Kotecha R, Djemil T, Tendulkar RD, Reddy CA, Thousand RA, Vassil A, et al. Dose-escalated stereotactic body radiation therapy for patients with intermediate- and high-risk prostate cancer: initial dosimetry analysis and patient outcomes. Int J Radiat Oncol Biol Phys. 2016;95(3):960–4.

    Article  PubMed  Google Scholar 

  68. King CR, Freeman D, Kaplan I, Fuller D, Bolzicco G, Collins S, et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol. 2013;109(2):217–21.

    Article  PubMed  Google Scholar 

  69. Morris WJ, Tyldesley S, Rodda S, Halperin R, Pai H, Michael M, et al. Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2017;98(2):275–85.

    Article  PubMed  Google Scholar 

  70. Kishan AU, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, et al. Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with Gleason score 9-10 prostate cancer. JAMA. 2018;319(9):896–905.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada

    Amandeep S. Taggar

  2. Sunnybrook Health Sciences Centre, Toronto, ON, Canada

    Paveen Mann

  3. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Michael J. Zelefsky

Authors
  1. Amandeep S. Taggar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paveen Mann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael J. Zelefsky
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amandeep S. Taggar .

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, USA

    Michael J. Zelefsky

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Crown

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Taggar, A.S., Mann, P., Zelefsky, M.J. (2019). Overview of Tumor Control Outcomes with Prostate SBRT for Low and Intermediate Risk Prostate Cancer and Comparison to Other Treatment Interventions. In: Zelefsky, M. (eds) Stereotactic Radiosurgery for Prostate Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-92453-3_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-92453-3_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-92452-6

  • Online ISBN: 978-3-319-92453-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation